Clinical Trials About "BioniCare Australasia" RSS

12:40 EST 12th November 2018 | BioPortfolio

We list hundreds of Clinical Trials about "BioniCare Australasia" on BioPortfolio. We draw our references from global clinical trials data listed on and refresh our database daily.

More Information about "BioniCare Australasia" on BioPortfolio

We have published hundreds of BioniCare Australasia news stories on BioPortfolio along with dozens of BioniCare Australasia Clinical Trials and PubMed Articles about BioniCare Australasia for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of BioniCare Australasia Companies in our database. You can also find out about relevant BioniCare Australasia Drugs and Medications on this site too.

Showing "BioniCare Australasia" Clinical Trials, all 6


STOP-AUST: The Spot Sign and Tranexamic Acid On Preventing ICH Growth - AUStralasia Trial

The aim of the study is to test if intracerebral haemorrhage (ICH) patients who have contrast extravasation on computed tomography angiography, the "spot sign", have lower rates of haematoma growth when treated with tranexamic acid within 4.5 hours of stroke onset, compared to placebo.

Comparative Study of Laparoscopic Versus Open Operations for Colon Cancer

The purpose of this study is to compare the short and long term outcomes of people who have colon cancers removed either by laparotomy (a large cut in the abdominal wall) or by a laparoscopic assisted approach (keyhole surgery). This study involves 37 credentialled surgeons in 20 approved hospitals across Australasia and during the recruitment period (Jan 1998 to March 2005) 601 patients were recruited into the ALCCaS Trial.

Probably Relevant

Real World Outcomes Study of Hepatic Encephalopathy Patients' Experience on Rifaximin (PROSPER)

This study evaluates hepatic encephalopathy (HE) and liver-related hospitalization rates and duration of stay in patients with HE treated with rifaximin-α 550mg compared to patients receiving other therapies. This registry study aims to comprehensively and rigorously characterize the impact of rifaximin-α 550 mg on hospitalization, clinical safety and effectiveness outcomes, and quality of life in patients with HE in Europe and Australasia.

Penicillin Against Flucloxacillin Treatment Evaluation

There is theroretical superiority with benzylpenicillin over orther anti-staphylococcal penicillins (ASP) for treatment of penicillin susceptible S. aureus (PSSA) infections due to a lower MIC distribution when compared with ASPs active against PSSA, combined with the ability to obtain higher levels of free non-protein-bound plasma drug concentrations. Although the data to support this theoretical advantage is limited, many clinicians in Australia (and worldwide) use benzylpeni...

Predicting Complications in Women With Toxaemia

Short description of the primary purpose of the protocol intended for the lay public. Include brief statement of study hypothesis In North America, pre-eclampsia ('toxaemia of pregnancy') is the most common cause for women to die during or shortly after pregnancy. It is also the most common reason for babies who are otherwise doing well to be delivered prematurely; this is with the intent purpose of protecting maternal health and safety. In many ways it is similar to the syste...

Champy Versus AO for Mandible Fractures

Patients who sustain a broken lower jaw have traditionally been treated in one of three ways. The first involves having their teeth and jaws being wired together for a period of 4 to 6 weeks in order to allow the broken jaw to heal. The second and third ways involve a surgical procedure that requires exposing the broken bones and stabilizing them with metal plates and screws that allow the patient to be able to function relatively normally during the healing period. One surgica...

More From BioPortfolio on "BioniCare Australasia"

Quick Search